Reports
Sale
Global Lyme Disease Diagnostics Market Share, Size, Growth, Trends, Forecast: By Diagnostic Technology: Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining, Nucleic Acid Test; By End User: Hospitals, Clinical Laboratories, Others; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Global Lyme Disease Diagnostics Market Outlook
The global Lyme disease diagnostics market size reached a value of around USD 2.5 billion in 2023. The market is further expected to grow at a CAGR of 6.86% during the forecast period of 2024-2032, likely to attain a value of around USD 4.5 billion by 2032.
Lyme Disease Diagnostics: Introduction and Insights
Lyme disease, also known as Lyme borreliosis, is an infectious disease which is caused due to a bacteria called Borrelia and is carried by ticks, especially blacklegged ticks. The most common indications and symptoms of the condition include erythema migrans, which are rapidly spreading red rashes. These symptoms or indications usually show up a week post the tick bite. The diagnostic tests of the condition include serological test, immunofluorescence (IFA), polymerase chain reaction (PCR) testing, and lymphocyte transformation test, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Timely diagnosis of Lyme disease is extremely important, if left untreated, Lyme disease can intensify and effect different organs of the body and cause further symptoms like headaches and joint/body pain, among other issues.
Key Trends in the Lyme Disease Diagnostics Market
The growth of the market is primarily driven the rising prevalence of Lyme disease across the globe, with the United States alone registering nearly 400,000 cases every year. Other than the rising prevalence, the growth of the market is also driven by the rapid growth in technological advancements, like immunoassay techniques, Next-Generation Sequencing (NGS), and PCR, among others.
The growth of the market can also be attributed to the rising healthcare expenditure by the government and private organisations. The are investing more into the development of diagnostic centres and healthcare facilities. Various organisations are also taking initiatives to further raise the awareness about the disease and the available treatments. The rising investment and funding by the government and different corporations has been contributing significantly to the growth of the market.
Global Lyme Disease Diagnostics Market Analysis
Based on type, the market is divided into diagnostic technology, end user, and region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnostic Technology
- Serological Test
- ELISA
- Western Blot
- Lymphocytic Transformation Test
- Urine Antigen Testing
- Immunofluorescent Staining
- Nucleic Acid Test
Market Breakup by End User
- Hospitals
- Clinical Laboratories
- ther End-Users
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Lyme Disease Diagnostics Market Scenario
Based on diagnostic technology, the serological test is anticipated to lead the global market owing to the higher efficiency of the test as compared to the other types.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Among the regional market, North America is anticipated to lead the global Lyme disease diagnostics market owing to the rising prevalence of the disease within the region. The region is anticipated to continue bolstering the global market owing to the increasing awareness about the condition and the importance of timely treatment. Better technologies are enabling enhanced diagnosis of the condition, which is likely to aid the growth of the market further in the forecast period.
Europe and Asia Pacific are also witnessing higher number of infections and are likely to witness growth in the coming years due to the rising awareness and the rising development of the healthcare infrastructure in the region.
Competitive Landscape
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model, along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global Lyme disease diagnostics market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Abbott Laboratories
- Bio-Rad Laboratories
- Covance Inc.
- Fres F. Hoffmann-La Roche AG
- T2 Biosystems
- Oxford Immunotec
- Baxter
- Fresenius Medical Care
- Bolder Biotechnology, Inc.
- Roche Holding AG
- Siemens AG
- Immunetics Inc
- GlaxoSmithKline Pharmaceuticals
- Canon Lifesciences
- Covance
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostic Technology |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Lyme Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Lyme Disease Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Lyme Disease Epidemiology (2016-2031)
5.3 Europe Lyme Disease Epidemiology (2016-2031)
5.4 Asia Pacific Lyme Disease Epidemiology (2016-2031)
5.5 Latin America Lyme Disease Epidemiology (2016-2031)
5.6 Middle East and Africa Lyme Disease Epidemiology (2016-2031)
6 Global Lyme Disease Diagnostics Market Overview
6.1 Global Lyme Disease Diagnostics Market Historical Value (2017-2023)
6.2 Global Lyme Disease Diagnostics Market Forecast Value (2024-2032)
7 Global Lyme Disease Diagnostics Market Landscape
7.1 Global Lyme Disease Diagnostics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Lyme Disease Diagnostics Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Global Lyme Disease Diagnostics Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Lyme Disease Diagnostics Market Segmentation
9.1 Global Lyme Disease Diagnostics Market by Diagnostic Technology
9.1.1 Market Overview
9.1.2 Serological Test
9.1.2.1 ELISA
9.1.2.2 Western Blot
9.1.3 Lymphocytic Transformation Test
9.1.4 Urine Antigen Testing
9.1.5 Immunofluorescent Staining
9.1.6 Nucleic Acid Test
9.2 Global Lyme Disease Diagnostics Market by End User
9.2.1 Market Overview
9.2.2 Hospitals
9.2.3 Clinical Laboratories
9.2.4 Other End-Users
9.3 Global Lyme Disease Diagnostics Market by Region
9.3.1 Market Overview
9.3.2 North America
9.3.3 Europe
9.3.4 Asia Pacific
9.3.5 Latin America
9.3.6 Middle East and Africa
10 North America Lyme Disease Diagnostics Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Lyme Disease Diagnostics Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Lyme Disease Diagnostics Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Lyme Disease Diagnostics Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Lyme Disease Diagnostics Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Abbott Laboratories
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Bio-Rad Laboratories
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Covance Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Fres F. Hoffmann-La Roche AG
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 T2 Biosystems
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Oxford Immunotec
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Baxter
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Fresenius Medical Care
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Bolder Biotechnology, Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Roche Holding AG
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Siemens AG
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Immunetics Inc
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 GlaxoSmithKline Pharmaceuticals
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Canon Lifesciences
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Covance
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Lyme Disease Diagnostics- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 2.5 billion in 2023, driven by the rising cases of Lyme disease across the globe.
The market is anticipated to grow at a CAGR of 6.86% during the forecast period of 2024-2032 to attain a value of around USD 4.5 billion by 2032.
The growth of the market is driven by factors like rising awareness about the disease, the increasing availability of the treatment, and the rapid technological advancements.
The key trends which are bolstering the market growth include the rising investment and fundings by government and organizations.
The diagnostic technologies in the market include the serological test, lymphocytic transformation test, urine antigen testing, immunofluorescent staining, and nucleic acid test. Serological tests can be further categorised into ELISA and western blot.
The end-users in the market include hospitals and clinical laboratories, among others.
The major regional markets include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
The key players in the market can be categorised into Abbott Laboratories, Bio-Rad Laboratories, Covance Inc., Fres F. Hoffmann-La Roche AG, T2 Biosystems, Oxford Immunotec, Baxter, Fresenius Medical Care, Bolder Biotechnology, Inc., Roche Holding AG, Siemens AG, Immunetics Inc, GlaxoSmithKline Pharmaceuticals, Canon Lifesciences, and Covance.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER